International Stroke Conference 2025  /  Risk Factors and Prevention Moderated Poster Tour I  /  Atrial Cardiopathy Biomarkers and Brain Infarction in Multiple Territories in ARCADIA
Logo

American Heart Association

  1
  0

Final ID: WMP101

Atrial Cardiopathy Biomarkers and Brain Infarction in Multiple Territories in ARCADIA

Abstract Body: Introduction: The ARCADIA trial (Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy) found no benefit of anticoagulation for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. It remains unclear if the biomarkers used in the trial reliably identified atrial cardiopathy. We examined the association between biomarkers of atrial cardiopathy and acute brain infarction in multiple arterial territories, an imaging signature of cardioembolic stroke.

Hypothesis: Biomarkers of atrial cardiomyopathy are associated with acute brain infarction in multiple arterial territories.

Methods: The ARCADIA trial screened patients with cryptogenic stroke for atrial cardiopathy at 185 centers in the U.S. and Canada. Investigators were asked to record the presence and topography of acute brain infarction on baseline imaging. Multi-territorial infarction was defined as acute infarction in at least two of the left middle cerebral artery (MCA), right MCA, and posterior circulation. P-wave terminal force in ECG lead V1 (PTFV1) and left atrial dimension index (LADI) were modeled as continuous variables, whereas N-terminal pro-B-type natriuretic peptide (NT-proBNP) was log-transformed. Relative risk regression was used to examine the association between atrial cardiopathy biomarkers and multi-territorial infarction.

Results: Of 3,745 patients enrolled in ARCADIA, 3,301 had available data on atrial cardiomyopathy biomarkers and the topography of acute infarctions seen on baseline imaging. Of these 3,301 patients, 452 (13.7%) had multi-territory brain infarction. We found no association with multi-territory brain infarction for ln(NT-proBNP) (OR per SD, 1.06; 95% CI, 0.97-1.16), PTFV1 (OR per SD, 1.06; 95% CI, 0.98-1.15), or LADI (OR per SD, 0.95; 95% CI, 0.86-1.05). Patients who met criteria for atrial cardiopathy and were randomized into the treatment phase of the study had a similar likelihood of multi-territorial infarction (13.4%) compared with those who were not eligible for randomization (13.8%) (P = 0.77).

Conclusions: The atrial cardiopathy biomarkers used in the ARCADIA trial were not associated with patterns of brain infarction suggestive of a cardioembolic source.
  • Gologorsky, Rachel  ( Weill Cornell Medicine , New York , New York , United States )
  • Karunamuni, Nilushi  ( Weill Cornell Medicine , New York , New York , United States )
  • Longstreth, W  ( University of Washington , Seattle , Washington , United States )
  • Tirschwell, David  ( University of Washington , Seattle , Washington , United States )
  • Elkind, Mitchell  ( Columbia University , New York , New York , United States )
  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
    • Author Disclosures:
    Rachel Gologorsky: DO NOT have relevant financial relationships | Nilushi Karunamuni: DO NOT have relevant financial relationships | W Longstreth: No Answer | David Tirschwell: DO have relevant financial relationships ; Consultant:AbbVie:Past (completed) ; Research Funding (PI or named investigator):Abbott:Active (exists now) | Mitchell Elkind: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS-Pfizer Alliance for Eliquis:Past (completed) ; Employee:American Heart Association:Active (exists now) ; Advisor:Atria Academy of Science and Medicine:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Past (completed) ; Research Funding (PI or named investigator):Roche:Past (completed) | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Risk Factors and Prevention Moderated Poster Tour I

Wednesday, 02/05/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
Effect Of A Bone Morphogenetic Protein Receptor Type 2 Mutation On The Cardiomyocyte Response To Pressure Overload

Llucia-valldeperas Aida, Van Wezenbeek Jessie, Smal Rowan, Bekedam Fjodor, Vonk Noordegraaf Anton, Bogaard Harm, De Man Frances

Flow cytometry thrombus biomarkers for improved cardioembolic etiology prediction in patients with cryptogenic stroke: a sub-analysis of the ITACAT study

Canals Pere, Garcia-tornel Garcia-camba Alvaro, Rodriguez-villatoro Noelia, Rubiera Marta, Boned Sandra, Muchada Marian, Olive-gadea Marta, Lozano Prudencio, Coscojuela Pilar, Li Jiahui, Sanjuan Estela, Juega Jesus, Dorado Laura, Hernandez-perez Maria, Quesada Helena, Cardona Pedro, De La Torre Carolina, Gallur Laura, Alvarez Sabin Jose, Molina Carlos, Pagola Jorge, Ribo Marc, Melgarejo Laura, Palacio Carlos, Rodriguez Maite, Rodriguez-luna David, Meza Burgos Claudia Patricia, Requena Manuel

More abstracts from these authors:
Infarct Topography, Effect of Anticoagulation, and Recurrence after Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial

Karunamuni Nilushi, Gologorsky Rachel, Longstreth W, Tirschwell David, Elkind Mitchell, Kamel Hooman

Risk of Recurrent Ischemic Stroke Among Patients with Cryptogenic Stroke and Left Ventricular Ejection Fraction <50%: A Secondary Analysis of the ARCADIA Trial

Jillella Dinesh, Merkler Alexander, Nahab Fadi, Sharma Richa, Zhang Cenai, Elkind Mitchell, Kamel Hooman, Kronmal Richard, Longstreth W, Tirschwell David, Di Tullio Marco

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)